Novartis gets FDA approval for MS drug Extavia. Extavia is essentially re-branded Betaseron, and marks the entry of a new (and large player) into the MS market. It’s Novartis’ MS pipeline that’s really interesting.
Plus, FDA grants temporary approval for Protalix‘s Gaucher disease treatment. Genzyme’s woes means that a new source was needed stat.
CSL Behring gets approval for Helixate FS (for children with hemophilia).
Shire gets creative with some adult ADHD outreach/educational programs.
And…this isn’t pharma at all. Just thought I’d toss in this quick blog post from this morning, on Successful Calls to Action (from my StickyFigure marketing blog). How did Chris Brogan and my dentist both make me take action?
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply